Improving care for older patients undergoing bladder cancer surgery
Official title: Comprehensive Geriatric Assessment for Perioperative Optimization in Cystectomy
Run by Aarhus University Hospital · NCT05679557 · Data updated 2026-11-12
This study tests if a detailed health check and support from a geriatric team can help older patients with bladder cancer have better surgery outcomes and recovery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 65 Years and up |
| Sex | All |
| Enrollment | 140 (estimated) |
| Sponsor | Aarhus University Hospital Academic / other |
| Locations | 1 site (Odense) |
| Status | Recruiting |
| Started | February 1, 2023 |
| Main results expected | April 1, 2026 |
| Study ends | April 1, 2027 |
| Registry record updated | February 27, 2026 |
| Trial ID | NCT05679557 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are older adults aged 65 and above with muscle-invasive bladder cancer who are considered frail based on the G8 screening tool.
✕Probably not a fit
Patients who are not frail, do not speak or understand Danish, or are undergoing other major surgical interventions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the impact of a Comprehensive Geriatric Assessment (CGA) on older patients with muscle-invasive bladder cancer scheduled for radical cystectomy. Participants will be randomly assigned to either a control group receiving standard care or an intervention group receiving a thorough preoperative geriatric assessment and tailored interventions. The intervention aims to optimize health issues that may affect surgical outcomes, with ongoing support from a geriatric team during the postoperative period. This approach emphasizes interdisciplinary collaboration to enhance patient care.
Why it matters
Potential benefit: If successful, this study could significantly reduce perioperative complications and improve outcomes for older patients undergoing bladder cancer surgery.
How similar studies have gone: Other studies have shown promising results with similar geriatric assessment approaches in surgical settings, indicating potential for success in this novel application.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with muscle-invasive bladder cancer and scheduled radical cystectomy. 2. Planned urinary diversion with an ileal conduit 3. Age ≥ 65 years. 4. Patients considered frail by G8 screening tool (total score ≤14). Exclusion Criteria: 1. Patients who refuse or are not able to provide informed consent. 2. Patients who do not speak or understand Danish. 3. Planned concomitant nephroureterectomy or other major surgical intervention at the same time as RC
Where it's running
-
Odense University Hospital
Odense, Denmark Recruiting
Study contacts
- Principal investigator: Jørgen S Bjerggaard Jensen, Prof., DMSc — Aarhus University Hospital and Aarhus University
- Study coordinator: Jørgen Bjerggaard Jensen, Prof., DMSc
- Email: katans@rm.dk
- Phone: +45 30915525
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy
This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.
-
Urinary Cell-Free DNA Test for Urothelial Cancer Origin
This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.
-
BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy
This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.
-
Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion
This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.
-
Personalized 3D Tumoroids from Your Tumor to Test Treatments
Researchers are using patient tumor tissue and blood to grow personalized 3D, vascularized tumoroids with autologous immune cells to help tailor treatments for kidney, bladder, and prostate cancers.
-
Irreversible Electroporation for Recurrent Pelvic Tumors
This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.